Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces its participation as an exhibitor at the American College of Cardiology (ACC.26) Annual Scientific Session in New Orleans, LA, March 28–30, 2026.

Daxor will showcase its new, rapid, portable Blood Volume Analyzer (BVA). As the only FDA-cleared diagnostic providing greater than 95% accurate, direct quantification of a patient's total blood, plasma, and red cell volume, the BVA replaces subjective guesswork with definitive data. This precision is a critical benefit of BVA, particularly for health systems navigating the $3.5 billion annual Medicare burden of heart failure readmissions in the United States.